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Background: The role of adjuvant dose-intensive chemotherapy and its efficacy according to baseline features has
not yet been established.
Patients and methods: Three hundred and forty-four patients were randomized to receive seven courses of
standard-dose chemotherapy (SD-CT) or three cycles of dose-intensive epirubicin and cyclophosphamide (epirubicin
200 mg/m2 plus cyclophosphamide 4 mg/m2 with filgrastim and progenitor cell support). All patients were assigned
tamoxifen at the completion of chemotherapy. The primary end point was disease-free survival (DFS). This paper
updates the results and explores patterns of recurrence according to predicting baseline features.
Results: At 8.3-years median follow-up, patients assigned DI-EC had a significantly better DFS compared with those
assigned SD-CT [8-year DFS percent 47% and 37%, respectively, hazard ratio (HR) 0.76; 95% confidence interval
0.58–1.00; P = 0.05]. Only patients with estrogen receptor (ER)-positive disease benefited from the DI-EC (HR 0.61;
95% confidence interval 0.39, 0.95; P = 0.03).
Conclusions: After prolonged follow-up, DI-EC significantly improved DFS, but the effect was observed only in
patients with ER-positive disease, leading to the hypothesis that efficacy of DI-EC may relate to its endocrine effects.
Further studies designed to confirm the importance of endocrine responsiveness in patients treated with dose-
intensive chemotherapy are encouraged.
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introduction
The value of high-dose chemotherapy to treat breast cancer
remains an open question, and in fact conflicting results are
reported in the literature. Two studies showed significant
prolonged disease-free survival (DFS) [1, 2]; others showed only
a nonsignificant trend to improved DFS [3, 4] and others failed
to show any advantage for high-dose chemotherapy [5–7].
Potential limitations of available data include inadequate
patient selection, limited duration of follow-up and the
heterogeneity of regimens used. Mature studies were
designed in an era when adjuvant therapies were selected
according to risk factors: the higher the risk the more intensive
the treatment. Factors predictive of response, such as hormone
receptor expression for predicting response to endocrine
therapies, have become important in the selection of
adjuvant treatment of breast cancer [8]. Breast cancer is
now recognized as a heterogeneous disease in which the
chance that one treatment program will benefit all is not
realistic [9].
o
ri
g
in
a
l
a
rt
ic
le
*Correspondence to: Dr. M. Colleoni, Research Unit in Medical Senology, Department
of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy.
Tel. +39-02-57489970 Fax. +39-02-574829212; E-mail: marco.colleoni@ieo.it
ª The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org
Moreover, only a minority of published studies have been
reported with a median follow-up exceeding 5 years, yet such
prolonged follow-up is particularly important for the
assessment of delayed events seen among patients with
endocrine-responsive disease [10].
Finally, these studies used different strategies to increase the
dose of chemotherapy administered. Most delivered a single
course of myeloablative treatment with progenitor cell support
as consolidation after multiple initial cycles of conventional
dose chemotherapy [1, 3, 4]. Alternatively, in other studies
dose-intensive chemotherapy was given from the start of
treatment in order to have the best chance of killing relatively
resistant cancer cells [2].
In 1995, the International Breast Cancer Study Group
(IBCSG) initiated a clinical trial (Trial 15-95) to examine the
role of dose-intensive epirubicin and cyclophosphamide (DI-
EC) versus conventional adjuvant chemotherapy for patients
with high-risk early breast cancer [11]. Here, we report mature
results for women enrolled in IBCSG Trial 15-95 overall and
examine selected predictive features in order to identify patients
who might benefit from dose-intensive chemotherapy.
methods
study design
From July 1995 to March 2000, 344 premenopausal and young
postmenopausal (£65 years old) patients with histologically proven, high-
risk operable breast cancer were randomized to receive either standard-dose
chemotherapy (SD-CT) or DI-EC within 6 weeks of surgery as previously
reported [11]. Briefly, high-risk operable breast cancer was defined by one
or more of the following: ‡10 involved axillary lymph nodes, estrogen
receptor (ER)-negative tumors with five or more involved axillary lymph
nodes, or operable T3 tumors with five or more involved axillary lymph
nodes. ER status was determined by immunohistochemistry in most cases
(88%) and otherwise by ligand-binding assay. Tumors were classified as ER
negative based on an immunohistochemical (IHC) quantitative result of
<1% stained cells, an IHC qualitative assay result of ‘negative’ or
‘borderline’ or ligand-binding assay of <10 fmol/mg of cytosol protein. The
intention to carry out separate analyses according to ER status was
originally specified in the protocol.
SD-CT consisted of i.v. injections of doxorubicin 60 mg/m2 or epirubicin
90 mg/m2 and cyclophosphamide 600 mg/m2 (AC or EC, respectively)
every 3 weeks for four cycles. This was immediately followed by ‘classical’
CMF comprising oral cyclophosphamide 100 mg/m2 daily for 14 days and
i.v. injections of methotrexate 40 mg/m2 and fluorouracil 600 mg/m2 on
days 1 and 8 every 4 weeks for three cycles. DI-EC consisted of epirubicin
200 mg/m2 i.v. over 1 h on day 1 and cyclophosphamide 4 mg/m2 on day 2,
given as 1 mg/m2 i.v. over 30 min in four divided doses. DI-EC was given
every 3 weeks for three cycles. Once chemotherapy had finished, all patients
were assigned to receive tamoxifen 20 mg/day for 5 years.
Patients are being followed lifelong, with updates of disease and survival
status required yearly. The median follow-up is 8.3 years.
statistical methods
DFS was defined as time from randomization to any breast cancer
recurrence, a second primary malignancy, or death, whichever occurred
first. Overall survival (OS) was defined as time from randomization to date
of death from any cause. The Kaplan–Meier method was used to estimate
survival distribution for DFS and OS [12]. The two-sided log-rank test was
used to assess the statistical significance of treatment differences between
the survival distributions [13]. Univariate Cox proportional hazard models
(with treatment effect only) were used to estimate the hazard ratios (HRs).
Multivariate Cox models were carried out to detect the treatment effect
considering the baseline characteristics [14]. The interaction of treatment
and ER status cohorts was tested using a Cox model including treatment
effect, ER status, and the interaction term.
Subpopulation treatment effect pattern plot (STEPP) analysis was used
to investigate the pattern of differences in 5-year DFS percent between
treatment arms according to patient age at study entry for ER-positive and
ER-negative cohorts separately [15]. P values for the interaction tests of
age and treatment groups were provided based on simulations.
A cumulative incidence analysis, with secondary malignancy and death
without prior cancer events as competing events, was carried out to
evaluate the treatment effects on time to breast cancer recurrence [16].
The incidence of amenorrhea was compared using Fisher’s exact test.
OS and DFS by the achievement of amenorrhea were tested using
a landmark analysis [17] at 9 months. Time zero in the landmark analysis
was chosen a priori at 9 months.
results
The Trial 15-95 population, selected to be at high risk for
recurrence yet fit for dose-intensive therapy, consisted of
relatively young patients (96% age < 60), mainly
premenopausal (67%) and with disease that was predominantly
ER negative (56%) (Table 1). Patients also tended to have
high tumor burden (74% with ‡10 nodes positive, 70%
tumor size > 2 cm) and high tumor grade 3 (59%). In the
SD-CT group, 64% received epirubicin (EC) and the
remainder received doxorubicin (AC).
DFS and OS
At 8.3-years median follow-up, patients assigned DI-EC
showed a significantly better DFS than those assigned SD-CT
(Figure 1A). The 8-year DFS percents were 47% and 37%,
respectively, with the HR and 95% confidence interval of 0.76
[(0.58–1.00), P = 0.05] in favor of DI-EC. There was
a nonsignificant trend favoring DI-EC in OS, with 75 deaths
on DI-EC and 90 on SD-CT. The 8-year OS percents were
56% and 48%, respectively, with a HR of 0.76 [(0.56–1.03),
P = 0.07] in favor of DI-EC (Figure 1B).
A multivariate analysis was carried out considering the
baseline characteristics of age (<40 versus ‡40), menopausal
status, type of local surgery, ER status, tumor size, number of
involved axillary nodes, and tumor grade. After adjusting for
these covariates, there remained a trend in favor of DI-EC
[DFS HR 0.78 (0.59–1.03), P = 0.08; OS HR 0.77 (0.56–1.05),
P = 0.09].
sites of failure
Figure 2 presents the cumulative incidence of each of the
competing causes of first DFS failure [breast cancer recurrence,
secondary (non-breast) primary malignancy, or death without
prior cancer event]. The significant effect of DI-EC on
controlling breast cancer recurrence is evident (P = 0.01). More
patients receiving DI-EC developed second primary
malignancies (five in the DI-EC group and two in the SD-CT
group, P = 0.19) or died without prior cancer events (four in
the DI-EC group and one in the SD-CT group, P = 0.19).
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Table 2 lists sites of first failure according to assigned treatment
of all patients and according to ER status. A reduction in terms
of events in favor of DI-EC was observed overall (54.3% versus
64.3%) and in the population with ER-positive disease (43%
versus 63%). A reduced number of distant metastases was
observed among all patients assigned DI-EC (36.4% versus
49.1%) especially among patients with ER-positive disease
(29.1% versus 45.7%).
DFS according to ER status
Figure 3 shows Kaplan–Meier curves of DFS for the ER-
negative and ER-positive cohorts. For the ER-positive cohort,
there was a significant benefit for the DI-EC group (the 8-year
OS percents were 60% and 38%, respectively, with a HR of 0.61
[(0.39–0.95), P = 0.03]). By contrast, no treatment difference
was observed for the ER-negative cohort for DFS (the 8-year
OS percents were 37% and 37%, respectively, with a HR of 0.92
[(0.65–1.30), P = 0.62]), although the treatment-by-ER status
interaction was not statistically significant (P = 0.21).
For ER-positive and ER-negative patients separately,
a multivariate analysis was carried out on DFS allowing for the
baseline characteristics of age (<40 versus ‡40), menopausal
status, type of local surgery, tumor size, number of involved
axillary nodes, and tumor grade. The results are shown in
Table 3. A HR and 95% confidence interval of 0.54 [(0.34–
0.87), P = 0.01] in favor of DI-CT was observed only in ER-
positive disease.
amenorrhea and outcome
Information on menses was collected at baseline and every
3 months for the first 2 years, then every 6 months. Women
were classified as achieving amenorrhea if they reported no
menses during months 7 through 9 from randomization. A
total of 193 patients were assessable and included in this
analysis. The achievement of amenorrhea in premenopausal
patients was statistically higher for DI-EC compared with
SD-CT (92.6% versus 77.6%, P = 0.004). The magnitude of the
effect was larger in patients aged <40 years, in whom it was
85.4% versus 50.0% overall, and 93.8% versus 57.1% and
80% versus 45% in the cohorts of patients with ER-positive
and ER-negative disease, respectively.
No amenorrhea effects were detected on DFS and OS in this
landmark analysis either in all patients or subgroups of patients
defined by ER status and age (data not shown). However,
Table 1. Patient characteristics
SD-CT,
n (%)
DI-EC,
n (%)
Total,
n (%)
Total cases 171 173 344
ER
Negative 99 (58) 94 (54) 193 (56)
Positive 70 (41) 79 (46) 149 (43)
Unknown 2 (1) 0 (0) 2 (1)
Age (years)
<40 39 (23) 44 (25) 83 (24)
40–59 123 (72) 125 (73) 248 (72)
‡60 9 (5) 4 (2) 13 (4)
Premenopausal 115 (67) 117 (67) 232 (67)
Postmenopausal 56 (33) 56 (33) 112 (33)
Mastectomy no RT 57 (33) 69 (40) 126 (37)
Mastectomy + RT 55 (32) 56 (32) 111 (32)
Breast conservation no RT 2 (1) 1 (1) 3 (1)
Breast conservation + RT 57 (34) 47 (27) 104 (30)
Positive nodes
5–9 37 (22) 54 (31) 91 (26)
‡10 134 (78) 119 (69) 253 (74)
Tumor size (cm)a
<2 45 (26) 59 (34) 104 (30)
2–5 91 (54) 84 (49) 175 (51)
>5 33 (19) 30 (17) 63 (18)
Tumor gradeb
1 5 (3) 12 (7) 17 (5)
2 60 (35) 64 (37) 124 (36)
3 106 (62) 95 (56) 201 (59)
aTumor size unknown in two patients.
bHistological grade unknown in two patients.
SD-CT, standard-dose chemotherapy; DI-EC, dose-intensive epirubicin and
cyclophosphamide; ER, estrogen receptor; RT, radiation therapy.
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Figure 1. Disease-free survival (DFS) (A) and overall survival (B) comparing patients assigned to dose-intensive epirubicin and cyclophosphamide · 3 (DI-
EC) with patients assigned to standard-dose chemotherapy (SD-CT). The median follow-up was 8.3 years.
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among the 88 ER-positive patients, the group in which we
expected to see the amenorrhea effect, 77 (87.5%) achieved
amenorrhea, while only 11 (12.5%) did not, therefore limiting
the power to detect any amenorrhea-related effect.
DFS according to age within ER cohorts
The STEPP analysis in Figure 4 shows 5-year DFS percent for
DI-EC and SD-CT groups in overlapping subpopulations
defined by age at study entry, for ER-positive and ER-negative
cohorts, for all patients and for patients with ‡10 axillary
lymph nodes positive. Due to the small number of patients,
the STEPP plots showed large variability. Both ER-positive and
ER-negative cohorts randomized to DI-EC showed higher
5-year DFS percent than those randomized to SD-CT, except in
older patients. Younger patients (age <40) with ER-positive
disease appeared to benefit most from DI-EC, but the
interaction of age and treatment was not statistically
significant (P = 0.54).
discussion
IBCSG Trial 15-95 is one of the few trials designed to compare
immediate multiple cycle dose-intensive chemotherapy with
standard-dose adjuvant chemotherapy. The results illustrate
that the average effect observed in the trials overall may be the
result of different treatment effects in different subpopulations.
Moreover, although a prolonged follow-up is required in order
to properly address the role of relapses in the endocrine-
responsive population [10], few studies available in the
literature report prolonged observation. Here, we present
results after a prolonged follow-up (8.3 years).
On average, DI-EC had a significantly better DFS compared
with SD-CT, supporting the role of dose-intensive
chemotherapy in the adjuvant therapy of high-risk breast
cancer. However, our results suggest a different pattern of
outcome according to the degree of potential endocrine
responsiveness, in that the benefit from DI-EC was evident only
among the cohort of patients with ER-positive tumors.
Several other clinical studies have provided evidence of
different interactions of chemotherapy with cellular growth
according to ER status. Studies of the therapeutic benefit of
ovarian function suppression by cytotoxic agents have yielded
controversial results, possibly related to the large variation in
chemotherapy dose intensity and duration as well as to
different patient characteristics [18–21]. Recently, however, two
randomized trials showed statistically significant increases in
Table 2. Sites of first treatment failure
SD-CT,
n (%)
DI-EC,
n (%)
Total,
n (%)
All patients 171 173 344
Total failures 110 (64.3) 94 (54.3) 204 (59.3)
Total deaths from any cause 90 (54.6) 75 (45.5) 165 (48.0)
Sites of first failure
Local 9 (5.3) 10 (5.8) 19 (5.5)
Contralateral 6 local 2 (1.2) 4 (2.3) 6 (1.7)
Regional 6 above 11 (6.4) 6 (3.5) 17 (4.9)
Distant 6 above 84 (49.1) 63 (36.4) 147 (42.7)
Soft tissue 6 above 5 (2.9) 5 (2.9) 10 (2.9)
Bone 6 above 29 (17.0) 12 (6.9) 41 (11.9)
Viscera 6 above 50 (29.2) 46 (26.6) 96 (27.9)
Second (non-breast)
malignancy
2 (1.2) 5 (2.9) 7 (2.0)
Death without prior
cancer event
1 (0.6) 4 (2.3) 5 (1.5)
Unknown 0 (0) 1 (0.6) 1 (0.3)
ER-positive cohort 70 79 149
Total failures 42 (60.0) 34 (43.0) 76 (51.0)
Total deaths from any cause 32 (45.7) 22 (27.9) 54 (36.2)
Sites of first failure
Local 2 (2.9) 4 (5.1) 6 (4.0)
Contralateral 6 local 1 (1.4) 2 (2.5) 3 (2.0)
Regional 6 above 5 (7.1) 0 (0) 5 (3.4)
Distant 6 above 32 (45.7) 23 (29.1) 55 (36.9)
Soft tissue 6 above 2 (2.9) 0 (0) 2 (1.3)
Bone 6 above 12 (17.1) 5 (6.3) 17 (11.4)
Viscera 6 above 18 (25.7) 18 (22.8) 36 (24.2)
Second (non-breast)
malignancy
1 (1.4) 3 (3.8) 4 (2.7)
Death without prior
cancer event
1 (1.4) 1 (1.3) 2 (1.3)
ER-negative cohort 99 94 193
Total failures 67 (67.7) 60 (63.8) 127 (65.8)
Total deaths from any cause 58 (58.6) 53 (56.4) 111 (57.5)
Sites of first failure
Local 7 (7.1) 6 (6.4) 13 (6.7)
Contralateral 6 local 1 (1.0) 2 (2.1) 3 (1.6)
Regional 6 above 5 (5.1) 6 (6.4) 11 (5.7)
Distant 6 above 52 (52.5) 40 (42.6) 92 (47.7)
Soft tissue 6 above 3 (3.0) 5 (5.3) 8 (4.1)
Bone 6 above 17 (17.2) 7 (7.4) 24 (12.4)
Viscera 6 above 32 (32.3) 28 (29.8) 60 (31.1)
Second (non-breast)
malignancy
1 (1.0) 2 (2.1) 3 (1.6)
Death without prior
cancer event
0 (0) 3 (3.2) 3 (1.6)
Unknown 0 (0) 1 (1.1) 1 (0.5)
SD-CT, standard-dose chemotherapy; DI-EC, dose-intensive epirubicin and
cyclophosphamide.
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Figure 2. Cumulative incidence of competing causes of failure according
to treatment.
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both the incidence of amenorrhea and DFS for very young
patients (those aged 39 years or younger) with ER-positive
tumors who received 6 months of standard-dose chemotherapy
[22, 23]. In addition, results of a large National Surgical
Adjuvant Breast and Bowel Project (NSABP) trial (B-30)
indicated that prospectively studied amenorrhea was associated
with improved DFS and OS irrespective of the type of
chemotherapy used [24]. The incidence of amenorrhea was
meticulously studied in Trial 15-95, and we found that
achieving amenorrhea was significantly higher in patients who
received DI-EC, particularly among patients aged <40 years. A
STEPP analysis, conducted in order to ascertain the magnitude
of the effect of DI-EC in patients with ER-positive tumors
according to age, showed a visual trend suggesting a larger
effect for DI-EC in younger patients (Figure 4), therefore
supporting a possible correlation between the achievement of
ovarian function suppression and efficacy of DI-EC.
Other studies exploring the activity of high-dose
chemotherapy described a more pronounced effect of high-
dose chemotherapy in younger patients [25] and in those with
disease features typical of endocrine-responsive disease (e.g.
low grade and HER2-negative disease) [26], although precise
analyses according to endocrine responsiveness, menstrual
status, type of treatment, and outcome are seldom available. In
these studies, the delayed time course of improved DFS in
patients treated with high-dose chemotherapy was reminiscent
of that observed with endocrine treatments.
Cytotoxic therapy may have an endocrine effect in
postmenopausal women through suppression of adrenal
function [27] perhaps partly due to increased supportive use
of corticosteroids.
The West German Study Group (WSG) AM-01 trial used, as
the present study, an early multiple cycle dose intensification
strategy in adjuvant therapy of breast cancer [2]. Their phase III
trial compared a dose-dense chemotherapy regimen with an up
front epirubicin-based double high-dose chemotherapy
regimen in 403 patients with early breast cancer. After a median
follow-up of 48.6 months, the 4-year event-free survival
(intention-to-treat analysis) was 60% (95% CI 53%–67%) in
the high-dose chemotherapy group and 44% (37%–52%) in the
control group (P = 0.00069). Retrospective subgroup analyses
showed benefit from high-dose chemotherapy independent of
hormone receptor status and age. Effects were more
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Figure 3. Disease-free survival (DFS) for estrogen receptor (ER)-positive (A) and ER-negative cohorts (B) comparing patients assigned to dose-intensive
epirubicin and cyclophosphamide · 3 (DI-EC) with patients assigned to standard-dose chemotherapy (SD-CT).
Table 3. DFS according to ER status
Multivariate Cox model results
Parameter Hazard ratio 95% CI P value
ER-positive cohort
DI-EC versus SD-CT 0.54 0.34–0.87 0.01
Age <40 versus ‡40 years 0.84 0.45–1.57 0.59
Postmenopausal versus
premenopausal
1.31 0.75–2.29 0.35
Mastectomy + RT versus
breast conservation
1.68 0.86–3.31 0.13
Mastectomy no RT versus
breast conservation
2.62 1.38–4.97 0.003
Tumor gradea 1.14 0.77–1.69 0.52
Number of involved
axillary nodesa
1.01 0.99–1.04 0.31
Tumor size* 1.09 0.98–1.21 0.10
ER-negative cohort
DI-EC versus SD-CT 0.91 0.64–1.30 0.60
Age <40 versus ‡40 years 1.03 0.67–1.60 0.88
Postmenopausal versus
premenopausal
0.88 0.58–1.35 0.57
Mastectomy + RT versus
breast conservation
1.12 0.68–1.84 0.65
Mastectomy no RT versus
breast conservation
1.14 0.73–1.78 0.57
Tumor gradea 1.07 0.75–1.54 0.71
Number of involved
axillary nodesa
1.03 1.01–1.05 0.01
Tumor sizea 1.00 0.92–1.09 0.96
aTumor grade, number of involved axillary nodes, and tumor size were
included in the model as continuous variables.
DFS, disease-free survival; ER, estrogen receptor; CI, confidence interval;
DI-EC, dose-intensive epirubicin and cyclophosphamide; SD-CT, standard-
dose chemotherapy; RT, radiation therapy.
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pronounced in young patients, but no data are available on the
effect according to age, amenorrhea in endocrine-responsive
disease, and in those with hormone receptor-negative disease. A
subsequent analysis carried out on paraffin-embedded tumors
from 236 patients confirmed a superior efficacy of high-dose
therapy in the subgroup of triple-negative and/or grade 3
tumors [28]. The difference between this effect and our
observations of superior efficacy among patients with
ER-positive disease may be related to the difference in the
conventional arm used, which comprised a dose-dense regimen
used for 3 months. This treatment duration may be
suboptimal in patients with endocrine-non-responsive
disease [29].
A recent meta-analysis of individual patient data from 15
randomized adjuvant breast cancer trials including 6210
patients [30] showed that after a median follow-up of 6 years,
high-dose chemotherapy significantly prolonged DFS (HR 0.87;
95% CI 0.81–0.94; P = 0.0001). After adjusting for steroid
hormone receptor content in the subgroup of patients for
whom it was available, a significant DFS benefit for high-dose
chemotherapy (HR 0.83; 95% CI 0.77–0.90; P < 0.0001) was
observed with no reported interaction between steroid
hormone receptors and treatment of DFS. Several factors
may explain the different results achieved in the meta-analysis
if compared with the present study. The meta-analysis
estimates of the average magnitude of treatment effect are
derived from a mixture of evidence that combines the results of
different patients treated with different therapies and with
a large variation in the follow-up duration. Moreover, no
results are available according to menopausal status, and no
information was reported on the methods and cut-offs used
in the various studies for the determination of selected
prognostic factors (e.g. steroid hormone receptors).
A potential limitation of the present trial is the decision
(made in the early 1990s) to use tamoxifen in all patients
including those with ER-negative disease. We have data from
unplanned exploratory analyses of other trials suggesting that
tamoxifen administered sequentially after adjuvant
chemotherapy may have a detrimental effect on patients with
ER-absent tumors (HR 2.10; 95% CI 1.03–4.29; P = 0.04) [22].
It is therefore possible that a detrimental interaction effect of
tamoxifen with chemotherapy may have reduced any possible
advantage for DI-EC in patients with ER-negative disease in
our study.
The DI-EC treatment is clearly more toxic, with nearly all
patients experiencing grade 4 neutropenia and
thrombocytopenia, more time spent in the hospital, and four
treatment-related deaths [11]. As reported in the companion
quality-of-life study, patient’s self-reported detrimental
effects of quality of life were limited to the 3-month treatment
period, and recovery was sooner than on SD-CT [31].
However, reliable evidence of benefit is required to justify the
burden and expense of dose-intensive therapy. We did not
observe any benefit for patients with ER-negative disease,
and the results in patients with ER-positive disease raise the
hypothesis that efficacy of DI-EC may relate to its endocrine
effects. There are less costly ways of offering endocrine therapy
for patients with endocrine-responsive disease.
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Figure 4. Subpopulation treatment effect pattern plots (STEPPs) for overlapping age subgroups. The 5-year disease-free survival (DFS) percentages are
plotted for cohorts defined by estrogen receptor status (positive, left; negative, right) among all patients (A and B) and patients with ‡10 positive nodes (C
and D).
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In conclusion, the results of Trial 15-95 indicate that DI-EC
improved DFS although the benefit was largely dependent on
the endocrine responsiveness of the tumor. Despite the
impressive magnitude of the effect of DI-EC associated with
endocrine responsiveness, the compelling biological
explanations for this effect, and the balance between groups
with respect to prognostic factors, the potential for bias still
exists due to the retrospective nature of the evaluation and the
sample size of the study. Similar observations by several studies
represent a strong incentive to improve further analyses by
requiring more accurate and reliable assessments of tumor and
patient characteristics. If confirmed, patients with endocrine-
non-responsive disease would benefit most from trials of
molecularly targeted treatments, many of which act
synergistically with cytotoxic agents.
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